<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-31T00:00:00.000Z</news:publication_date>
      <news:title>AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>zh-tw</news:language>
      </news:publication>
      <news:publication_date>2026-07-31T00:00:00.000Z</news:publication_date>
      <news:title>安邦生技：免疫治療的「星鏈計畫」</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>zh-tw</news:language>
      </news:publication>
      <news:publication_date>2026-07-30T00:00:00.000Z</news:publication_date>
      <news:title>Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html</loc>
    <news:news>
      <news:publication>
        <news:name>Drugnews｜藥時事</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-30T00:00:00.000Z</news:publication_date>
      <news:title>After Xtandi: Can Astellas Build an Oncology Platform?</news:title>
    </news:news>
  </url>
</urlset>
